@nvillain-alz
Neurologue Chercheur | Neurologist Researcher | #Alzheimer #Dementia #Neurodegeneration | @fac-sante-sorbonne.bsky.social | @sorbonne-universite.fr | @pitiesalpetriere.bsky.social | @ap-hp.bsky.social | @institutducerveau.bsky.social
Traitement de la maladie d’Alzheimer par une chirurgie lympathicoveineuse du cou : l'AP-HP rappelle que cette technique n'est pas validée.
➡️Mise au point de l'AP-HP sur le traitement de la maladie d'Alzheimer par une chirurgie lymphaticoveineuse du cou.
En savoir plus : urlr.me/S87fhs
Chirurgie lymphaticoveineuse du cou et #Alzheimer : rappel de l’ @ap-hp.bsky.social
Technique NON validée, pas de soin hors protocole.
Priorité : essais contrôlés (ANSM, éthique) ; protéger les patients.
bsky.app/profile/ap-h...
Médicaments anti-Alzheimer, le débat est nécessaire : l’appel d’un collectif de scientifiques
➡️ https://l.lexpress.fr/r90
Merci au Dr @nvillain-alz.bsky.social pour sa présentation sur les nouveaux traitements par immunothérapie #alzheimer #traitements.
🎉 We’re now on BlueSky!
Follow the European Journal of Neurology 👉 @europeanjournalofneurology.ean.org
Stay up-to-date with the latest in #Neurology!
#MedSky #NeuroSky
Part 1 focused on patient selection challenges. Part 2 will focus on health system readiness. Tara Carlisle and myself were co-first authors on these and benefited greatly from our senior author, Kirk Daffner.
The American Neuropsychiatric Association (No bsky, yet..) dementia special interest group, which I've been the leader of for a number of years, has been working on a two part series for the Journal of Neuropsychiatry and Clinical Neuroscience. Part 1 here.
www.psychiatryonline.org/doi/10.1176/...
"We call on researchers worldwide to unite and join us ... If you love freedom, come and help us stay free," French President Emmanuel Macron said at Paris' Sorbonne University
#BrainDrain
www.reuters.com/science/eus-...
RV le 2 juin pour les #EntretiensAlzheimer : avancées de la recherche, nouveaux traitements, prédiction de la maladie… avec @nvillain-alz.bsky.social et #AudreyGabelle Gratuit sur inscription 👉 entretiensalzheimer.org/index.php/il...
Scientists must push back against the threat of rising white nationalism and the dangerous and pseudoscientific ideas of eugenics
https://go.nature.com/42Zryw1
🧠 PhD position available!
Study polypathology in the medial temporal lobe at the Paris Brain Institute with @lemwisse.bsky.social , @nvillain-alz.bsky.social and myself.
This exciting project combines neuroimaging, neuropathology and cognition!
Please share widely 🙏
Exciting opportunity for a PhD position at the @institutducerveau.bsky.social on a European collaborative project under the supervision of medial temporal lobe specialists!
Spread the word!
bsky.app/profile/lemw...
am pleased to share our letter, highlighting that the science does not yet support regulatory approval of amyloid-targeting therapies for AD based solely on biomarker evidence.
alz-journals.onlinelibrary.wiley.com/doi/full/10....
💊Les médicaments contre l’anxiété, c’est pour une courte durée. Ceux contre l’insomnie, c’est pour quelques nuits !
↪️Découvrez notre campagne pour favoriser le #BonUsage des médicaments contre l’anxiété et l’insomnie sévères👉http://lesmedicamentsetmoi.fr
#MedicamentsEtMoi #GCN2025
Absolutely! I'm celebrating for the 85%! :)
The favorable R/B ratio remains*
It could also be argued that this subgroup hasn't proved efficacy. Therefore, the R/B ratio remains to be proven considering the significant safety signal
2/
C) The key question: if excluded from treatment, what enhanced support/follow-up do we offer? What research for this vulnerable group?
The APOLLOE4 trial is an example of an active engagement into this direction!
1/ Indeed, an important milestone with EMA approval of lecanemab! Is it genetic discrimination? I beg to disagree :)
A) Not all inequality is inequity — in oncology, genetics often guides access.
B) Feels like double jeopardy: highest risk, yet denied treatment. But safety data matters.
Great news today. Lecanemab approved in Europe. I quibble with the fact that genetic discrimination is permitted, but this probably won’t last long.
I mean, now the decision relies on the European Commission directly as the dedicated committees could not make a decision
Here is the full list:
Ursula von der Leyen & Co
commission.europa.eu/about/organi...
« The European Commission (EC) is the primary executive arm of the European Union (EU). It operates as a cabinet government »
en.wikipedia.org/wiki/Europea...
10/ The science is on the table. The @ema.europa.eu's CHMP has spoken. The clinics are ready. It’s time for the @ec.europa.eu to act.
#Alzheimers #EuropeanCommission #lecanemab #EMA #neurology
9/ Full disclosure: I have no direct financial or strategic ties to the pharma industry. For transparency, see: www.transparence.sante.gouv.fr/pages/infosb...
8/ Lecanemab will not stop Alzheimer’s. But for a subset of patients, it is a step forward. Let’s not trip over our own feet.
7/ Patients cannot afford policy gridlock. In early AD, every month matters—not dramatically, but measurably. Delays shift more patients from “possibly eligible” to “definitely too late.”
6/ Disagreeing with CHMP? Fine—but then show us the arguments. Transparency, not opacity, is the only way forward if trust is to be preserved. 🧭
5/ Regulatory hesitations are understandable. But indecision at the @ec.europa.eu level now undermines trust, not just in regulation, but in our ability to act on science.